85 / 1851
Enrichment Design
•
Primarily for settings where the classifier is
based on a single gene whose protein product
is the target of the drug
–
eg trastuzumab
•
Analytical validation, biological rationale and
phase II data provide basis for regulatory
approval of the test
•
Phase III study focused on test + patients to
provide data for approving the drug